NYSE:BSX - Boston Scientific Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $43.80
  • Forecasted Upside: 29.62 %
  • Number of Analysts: 24
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 18 Buy Ratings
  • 3 Strong Buy Ratings
$33.79
▲ +0.46 (1.38%)
1 month | 3 months | 12 months
Get New Boston Scientific Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BSX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BSX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$43.80
▲ +29.62% Upside Potential
This price target is based on 24 analysts offering 12 month price targets for Boston Scientific in the last 3 months. The average price target is $43.80, with a high forecast of $58.00 and a low forecast of $25.00. The average price target represents a 29.62% upside from the last price of $33.79.
Buy
The current consensus among 24 investment analysts is to buy stock in Boston Scientific. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 2 strong buy ratings
  • 19 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/4/2019
  • 2 strong buy ratings
  • 17 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/2/2019
  • 1 strong buy ratings
  • 16 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/1/2019
  • 2 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/29/2020
  • 3 strong buy ratings
  • 20 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/29/2020
  • 3 strong buy ratings
  • 19 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/27/2020
  • 3 strong buy ratings
  • 18 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/26/2020
  • 3 strong buy ratings
  • 18 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/25/2020

Latest Recommendations

  • 3 strong buy ratings
  • 18 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/18/2020TruistLower Price Target$47.00 ➝ $44.00Medium
i
11/18/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price Target$46.00 ➝ $43.00Medium
i
11/18/2020Smith Barney CitigroupLower Price Target$46.00 ➝ $43.00High
i
11/18/2020Wells Fargo & CompanyLower Price TargetOverweight$44.00 ➝ $41.00High
i
11/18/2020Morgan StanleyLower Price TargetOverweight$41.00 ➝ $40.00High
i
11/17/2020Needham & Company LLCLower Price TargetBuy$50.00 ➝ $43.00High
i
Rating by Michael Matson at Needham & Company LLC
10/29/2020Morgan StanleyLower Price TargetOverweight$48.00 ➝ $41.00High
i
9/17/2020TruistInitiated CoverageBuy$47.00 ➝ $47.00High
i
9/11/2020Wolfe ResearchInitiated CoverageMarket Perform$46.00Medium
i
7/30/2020Stifel NicolausBoost Price TargetBuy$45.00 ➝ $47.00Low
i
Rating by Rick Wise at Stifel Nicolaus
7/30/2020Jefferies Financial GroupBoost Price TargetBuy$43.00 ➝ $46.00Low
i
7/30/2020CitigroupBoost Price TargetBuy$44.00 ➝ $46.00Medium
i
7/30/2020SVB LeerinkBoost Price TargetMarket Perform$40.00 ➝ $43.00Medium
i
Rating by D. Antalffy at SVB Leerink LLC
7/30/2020Morgan StanleyBoost Price TargetOverweight$45.00 ➝ $48.00Medium
i
7/29/2020Needham & Company LLCReiterated RatingBuy$50.00Medium
i
Rating by Michael Matson at Needham & Company LLC
7/29/2020OppenheimerBoost Price TargetMarket Perform$41.00 ➝ $43.00Medium
i
6/24/2020Stifel NicolausReiterated RatingBuy$45.00Low
i
Rating by Rick Wise at Stifel Nicolaus
5/13/2020ArgusBoost Price TargetBuy$40.00 ➝ $42.00Low
i
4/30/2020CSFBBoost Price TargetOutperform$42.00 ➝ $43.00High
i
4/30/2020Wells Fargo & CompanyBoost Price TargetOverweight$40.00 ➝ $41.00Low
i
4/30/2020Credit Suisse GroupBoost Price TargetOutperform$42.00 ➝ $43.00Low
i
4/30/2020CitigroupBoost Price TargetBuy$40.00 ➝ $42.00Medium
i
4/30/2020UBS GroupLower Price TargetBuy$50.00 ➝ $45.00Medium
i
4/30/2020Stifel NicolausBoost Price TargetBuy$35.00 ➝ $45.00Medium
i
4/30/2020Raymond JamesBoost Price TargetStrong-Buy$42.00 ➝ $43.00High
i
4/30/2020OppenheimerReiterated RatingHold$46.00 ➝ $41.00Low
i
4/29/2020BTIG ResearchReiterated RatingBuy$44.00Low
i
Rating by Marie Thibault at BTIG Research
4/29/2020Needham & Company LLCReiterated RatingBuy$46.00Low
i
Rating by Michael Matson at Needham & Company LLC
4/23/2020SunTrust BanksLower Price TargetBuy$28.00 ➝ $25.00Low
i
4/22/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$40.00Low
i
Rating by D. Antalffy at SVB Leerink LLC
4/9/2020Raymond JamesLower Price TargetStrong-Buy$49.00 ➝ $42.00High
i
4/2/2020Piper SandlerReiterated RatingBuyLow
i
Rating by Matthew O'Brien at Piper Sandler
4/2/2020Needham & Company LLCLower Price TargetBuy$53.00 ➝ $43.00Medium
i
4/1/2020The Goldman Sachs GroupUpgradeNeutral ➝ Conviction-Buy$46.00 ➝ $38.00High
i
3/27/2020CitigroupLower Price TargetBuy$48.00 ➝ $40.00Low
i
3/24/2020Stifel NicolausLower Price TargetBuy$47.00 ➝ $30.00High
i
3/23/2020StephensLower Price TargetOverweight$48.00 ➝ $35.00High
i
Rating by Chris Cooley at Stephens
3/9/2020CfraUpgradeBuy ➝ Strong-Buy$50.00 ➝ $47.00Low
i
3/6/2020Credit Suisse GroupLower Price TargetOutperform$51.00 ➝ $46.00High
i
3/4/2020CitigroupInitiated CoverageBuy$48.00High
i
2/12/2020The Goldman Sachs GroupInitiated CoverageNeutral$46.00Low
i
2/6/2020BTIG ResearchInitiated CoverageBuy$46.00Low
i
2/6/2020Canaccord GenuityReiterated RatingBuy$58.00Low
i
1/15/2020CowenReiterated RatingBuy$52.00Medium
i
Rating by Josh Jennings at Cowen Inc
1/14/2020Piper SandlerReiterated RatingBuyLow
i
Rating by Matthew O'Brien at Piper Sandler
12/30/2019CowenBoost Price TargetOutperform$47.00 ➝ $52.00Low
i
12/20/2019JPMorgan Chase & Co.Boost Price TargetOverweight$50.00 ➝ $55.00Low
i
12/19/2019Needham & Company LLCDowngradeStrong-Buy ➝ Buy$53.00Low
i
Rating by Michael Matson at Needham & Company LLC
12/17/2019Morgan StanleyBoost Price TargetOverweight$50.00 ➝ $51.00Medium
i
Rating by David Lewis at Morgan Stanley
12/16/2019Wells Fargo & CompanyBoost Price TargetOverweight$48.00 ➝ $52.00Low
i
10/25/2019GuggenheimSet Price TargetBuy$53.00N/A
i
Rating by Christopher Pasquale at Guggenheim
10/23/2019Needham & Company LLCReiterated RatingBuy$53.00Medium
i
Rating by Michael Matson at Needham & Company LLC
10/14/2019Raymond JamesLower Price TargetStrong-Buy$50.00 ➝ $48.00Low
i
9/30/2019StephensSet Price TargetBuy$48.00Low
i
Rating by Chris Cooley at Stephens
9/6/2019Stifel NicolausSet Price TargetBuy$47.00High
i
Rating by Rick Wise at Stifel Nicolaus
9/5/2019JPMorgan Chase & Co.Initiated CoverageOverweightMedium
i
9/3/2019BarclaysReiterated RatingOverweight$48.00High
i
8/30/2019Stifel NicolausSet Price TargetBuy$46.00Low
i
Rating by Rick Wise at Stifel Nicolaus
8/29/2019Morgan StanleySet Price TargetBuy$50.00Low
i
Rating by David Lewis at Morgan Stanley
7/31/2019SVB LeerinkSet Price TargetBuy$50.00Low
i
Rating by Danielle Antalffy at SVB Leerink LLC
7/25/2019Raymond JamesBoost Price TargetStrong-Buy$48.00 ➝ $50.00Medium
i
7/24/2019Needham & Company LLCSet Price TargetBuy$46.00Low
i
Rating by Michael Matson at Needham & Company LLC
7/24/2019BTIG ResearchSet Price TargetBuy$46.00Low
i
Rating by Sean Lavin at BTIG Research
7/24/2019Piper Jaffray CompaniesSet Price TargetBuy$50.00Low
i
Rating by Matthew O'Brien at Piper Jaffray Companies
6/27/2019Stifel NicolausBoost Price TargetBuy ➝ In-Line$44.00 ➝ $46.00Medium
i
6/27/2019Canaccord GenuityBoost Price TargetBuy$43.00 ➝ $46.00Medium
i
6/27/2019Jefferies Financial GroupBoost Price TargetBuy ➝ Positive$44.00 ➝ $48.00Medium
i
6/27/2019Piper Jaffray CompaniesBoost Price TargetOverweight$42.00 ➝ $50.00Medium
i
6/18/2019Wells Fargo & CompanyBoost Price TargetOutperform$42.00 ➝ $45.00Medium
i
5/13/2019Evercore ISIUpgradeIn-Line ➝ Outperform$36.20Low
i
5/13/2019Needham & Company LLCReiterated RatingBuy$43.00Medium
i
4/25/2019BTIG ResearchReiterated RatingBuyHigh
i
4/17/2019Canaccord GenuityLower Price TargetBuy ➝ Buy$45.00 ➝ $43.00Medium
i
2/13/2019ArgusBoost Price TargetBuy$43.00 ➝ $45.00Medium
i
Rating by Jasper Hellweg at Argus
2/11/2019Canaccord GenuityReiterated RatingBuy$45.00Medium
i
2/8/2019SunTrust BanksReiterated RatingBuy$47.00Low
i
2/8/2019GuggenheimReiterated RatingBuy$48.00Low
i
2/6/2019Needham & Company LLCReiterated RatingBuy$43.00Low
i
1/8/2019Needham & Company LLCReiterated RatingBuy$43.00Medium
i
12/17/2018Credit Suisse GroupInitiated CoverageOutperform$42.00Low
i
11/27/2018UBS GroupInitiated CoverageBuy ➝ Buy$45.00High
i
11/21/2018OppenheimerReiterated RatingHoldLow
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
11/21/2018BTIG ResearchReiterated RatingBuyLow
i
11/20/2018SunTrust BanksBoost Price TargetBuy$44.00Low
i
11/19/2018StephensReiterated RatingIn-Line ➝ Market Perform$40.00Medium
i
11/16/2018GuggenheimBoost Price TargetBuy$45.00Low
i
10/26/2018ArgusBoost Price TargetBuy ➝ Buy$41.00 ➝ $43.00Low
i
Rating by Jasper Hellweg at Argus
10/25/2018Canaccord GenuityBoost Price TargetBuy$40.00 ➝ $42.00Low
i
10/25/2018BTIG ResearchReiterated RatingBuy$45.00Medium
i
10/24/2018OppenheimerSet Price TargetHold$38.00Medium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
10/22/2018CowenSet Price TargetBuy$39.00 ➝ $42.00Low
i
10/16/2018BTIG ResearchReiterated RatingBuy$45.00High
i
10/15/2018BarclaysInitiated CoverageOverweight ➝ Overweight$43.00High
i
10/15/2018Royal Bank of CanadaBoost Price TargetTop Pick$42.00High
i
10/2/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$38.00 ➝ $48.00Low
i
9/25/2018OppenheimerReiterated RatingHoldMedium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
9/17/2018Wells Fargo & CompanyBoost Price TargetOutperform$38.00 ➝ $42.00Low
i
9/7/2018Needham & Company LLCReiterated RatingStrong-Buy ➝ Strong-Buy$39.00 ➝ $43.00Low
i
9/5/2018ArgusBoost Price TargetBuy$41.00Low
i
9/4/2018Raymond JamesBoost Price TargetStrong-Buy ➝ Strong-Buy$40.00 ➝ $41.00Low
i
9/4/2018Jefferies Financial GroupUpgradeHold ➝ Buy$34.00 ➝ $42.00Low
i
7/27/2018GuggenheimReiterated RatingBuy$43.00Low
i
7/26/2018Stifel NicolausReiterated RatingBuy$37.00Low
i
7/26/2018Jefferies Financial GroupReiterated RatingHold$34.00Low
i
7/26/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$33.00 ➝ $38.00Low
i
7/26/2018Piper Jaffray CompaniesBoost Price TargetOverweight$38.00Low
i
7/23/2018Royal Bank of CanadaBoost Price TargetTop Pick$36.00Low
i
7/23/2018SunTrust BanksBoost Price TargetBuy$39.00Low
i
7/10/2018BMO Capital MarketsBoost Price TargetOutperform$36.00High
i
7/6/2018Needham & Company LLCReiterated RatingStrong-BuyMedium
i
6/27/2018Sanford C. BernsteinInitiated CoverageOutperform$38.00Low
i
6/7/2018ArgusBoost Price TargetBuy ➝ Buy$32.00 ➝ $36.00Medium
i
5/1/2018CitigroupBoost Price TargetBuy ➝ Buy$32.00 ➝ $34.00Low
i
4/26/2018Raymond JamesBoost Price TargetStrong-Buy ➝ Strong-Buy$32.00 ➝ $34.00Low
i
4/26/2018Jefferies Financial GroupReiterated RatingHold$31.00Low
i
4/26/2018Needham & Company LLCBoost Price TargetStrong-Buy ➝ Strong-Buy$35.00 ➝ $36.00Low
i
4/26/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$32.00 ➝ $33.00Low
i
4/26/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$31.00 ➝ $32.00Low
i
4/25/2018Canaccord GenuityReiterated RatingBuy$36.00Low
i
4/5/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$30.00 ➝ $34.00Low
i
3/27/2018Needham & Company LLCReiterated RatingBuy$35.00High
i
3/19/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $33.00Low
i
3/5/2018Royal Bank of CanadaReiterated RatingTop Pick$32.00Medium
i
2/23/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$31.00Medium
i
2/2/2018Jefferies Financial GroupReiterated RatingHold ➝ NeutralLow
i
1/17/2018Canaccord GenuityReiterated RatingBuyLow
i
1/16/2018Needham & Company LLCReiterated RatingBuy$32.00Low
i
1/10/2018BarclaysReiterated RatingBuy$32.00Low
i
1/5/2018Royal Bank of CanadaUpgradeOutperform ➝ Top PickMedium
i
1/3/2018Evercore ISIInitiated CoverageIn ➝ In-Line$27.00Medium
i
12/12/2017BMO Capital MarketsReiterated RatingBuy$32.00Low
i
12/8/2017Needham & Company LLCUpgradeBuy ➝ Strong-Buy$25.04 ➝ $32.00Low
i
12/4/2017SunTrust BanksSet Price TargetBuy$33.00Low
i
Rating by Bruce Nudell at SunTrust Banks, Inc.
11/30/2017CowenSet Price TargetBuy$31.00Low
i
Rating by Josh Jennings at Cowen Inc
11/30/2017BTIG ResearchUpgradeNeutral ➝ Buy$31.00Medium
i
11/29/2017BMO Capital MarketsReiterated RatingBuy$31.00Medium
i
11/29/2017JPMorgan Chase & Co.Reiterated RatingBuyLow
i
11/29/2017OppenheimerReiterated RatingHoldHigh
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
11/29/2017Canaccord GenuityLower Price TargetBuy ➝ Buy$36.00 ➝ $35.00High
i
11/7/2017Royal Bank of CanadaReiterated RatingBuy$31.00N/A
i
10/31/2017SunTrust BanksSet Price TargetBuy$34.00N/A
i
Rating by Bruce Nudell at SunTrust Banks, Inc.
10/27/2017BMO Capital MarketsBoost Price TargetOutperform$30.00 ➝ $32.00N/A
i
10/24/2017Canaccord GenuityInitiated CoverageBuy ➝ Buy$36.00N/A
i
10/13/2017BMO Capital MarketsReiterated RatingBuy$30.00N/A
i
10/3/2017Needham & Company LLCReiterated RatingBuy$32.00Low
i
10/2/2017SunTrust BanksReiterated RatingBuy$34.00Medium
i
9/25/2017Stifel NicolausReiterated RatingBuy$32.00Low
i
9/7/2017Jefferies Financial GroupReiterated RatingHoldLow
i
9/1/2017Royal Bank of CanadaReiterated RatingBuy$31.00N/A
i
8/9/2017OppenheimerReiterated RatingHoldMedium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/1/2017UBS GroupReiterated RatingBuy$30.00 ➝ $31.00Low
i
7/30/2017Stifel NicolausReiterated RatingBuy$32.00Medium
i
7/28/2017OppenheimerSet Price TargetHold$29.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
7/28/2017CowenReiterated RatingBuy$31.00 ➝ $32.00Low
i
7/17/2017CowenReiterated RatingOutperform$31.00Low
i
7/12/2017Royal Bank of CanadaReiterated RatingBuy$31.00Low
i
6/28/2017JPMorgan Chase & Co.Reiterated RatingOverweight$27.00 ➝ $31.00Low
i
6/28/2017Stifel NicolausBoost Price TargetHold$30.00 ➝ $32.00Low
i
6/28/2017Jefferies Financial GroupReiterated RatingHold$28.00Low
i
6/28/2017OppenheimerReiterated RatingHoldLow
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
6/28/2017BarclaysBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $31.00Low
i
6/22/2017Needham & Company LLCBoost Price TargetBuy$30.00 ➝ $32.00Low
i
6/21/2017BMO Capital MarketsReiterated RatingBuy$30.00Low
i
6/16/2017Wells Fargo & CompanyReiterated RatingOutperform$29.50 ➝ $31.00Low
i
6/9/2017Royal Bank of CanadaReiterated RatingOurperform$31.00 ➝ $29.00Low
i
6/9/2017Royal Bank of CanadaBoost Price TargetOutperform$29.00 ➝ $31.00Low
i
5/16/2017The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$28.00Low
i
4/28/2017Stifel NicolausBoost Price TargetBuy$28.00 ➝ $30.00Low
i
4/28/2017CowenBoost Price TargetOutperform$29.00 ➝ $31.00Low
i
4/28/2017Evercore ISIBoost Price TargetOutperform$26.50 ➝ $28.50Low
i
4/28/2017OppenheimerSet Price TargetHold$27.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
4/27/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$29.00 ➝ $30.00Low
i
4/12/2017GuggenheimReiterated RatingBuyLow
i
Rating by Christopher Pasquale at Guggenheim
4/7/2017Jefferies Financial GroupBoost Price TargetHold$26.00 ➝ $28.00Low
i
2/23/2017OppenheimerReiterated RatingHoldN/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
2/23/2017Needham & Company LLCReiterated RatingBuy$29.00N/A
i
2/23/2017Northland SecuritiesReiterated RatingPositiveN/A
i
2/5/2017BTIG ResearchReiterated RatingHoldN/A
i
2/3/2017OppenheimerSet Price TargetHold$25.00 ➝ $26.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
2/3/2017Jefferies Financial GroupReiterated RatingHold$26.00N/A
i
2/2/2017Needham & Company LLCBoost Price TargetBuy$28.00 ➝ $29.00N/A
i
1/8/2017BTIG ResearchReiterated RatingNeutralN/A
i
10/14/2016Royal Bank of CanadaReiterated RatingOutperform$28.00N/A
i
Rating by Glenn Novarro at Royal Bank of Canada
10/6/2016CitigroupBoost Price TargetBuy$28.00 ➝ $29.00N/A
i
9/1/2016ArgusUpgradeHold ➝ Buy$23.82 ➝ $33.00N/A
i
Rating by David Toung at Argus
8/3/2016CitigroupBoost Price TargetBuy$26.00 ➝ $28.00N/A
i
7/31/2016Evercore ISIReiterated RatingBuy$25.50 ➝ $26.00N/A
i
7/29/2016Royal Bank of CanadaReiterated RatingBuy$28.00N/A
i
7/29/2016JPMorgan Chase & Co.Boost Price TargetOverweight$24.00 ➝ $27.00N/A
i
Rating by Michael Weinstein at JPMorgan Chase & Co.
7/29/2016Credit Suisse GroupReiterated RatingBuyN/A
i
7/29/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
7/29/2016Jefferies Financial GroupBoost Price TargetHold$21.00 ➝ $24.00N/A
i
7/29/2016WedbushBoost Price TargetNeutral$23.00 ➝ $25.00N/A
i
7/29/2016Needham & Company LLCBoost Price TargetBuy$26.00 ➝ $28.00N/A
i
Rating by Michael Matson at Needham & Company LLC
7/28/2016BenchmarkBoost Price TargetBuy$25.00 ➝ $31.00N/A
i
Rating by Jan Wald at Benchmark Co.
7/17/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
Rating by Michael Weinstein at JPMorgan Chase & Co.
7/5/2016UBS GroupReiterated RatingBuy$25.00N/A
i
Rating by Matt Miksic at UBS Group AG
6/21/2016Piper Jaffray CompaniesReiterated RatingOverweight$26.00N/A
i
6/17/2016SVB LeerinkReiterated RatingBuy$25.50 ➝ $27.50N/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
6/8/2016GuggenheimInitiated CoverageBuy$26.00N/A
i
5/25/2016Piper Jaffray CompaniesReiterated RatingOverweight$26.00N/A
i
5/23/2016BTIG ResearchDowngradeBuy ➝ Neutral$24.20N/A
i
Rating by Sean Lavin at BTIG Research
5/12/2016Royal Bank of CanadaReiterated RatingOutperform$25.00N/A
i
Rating by Glenn Novarro at Royal Bank of Canada
4/28/2016BarclaysBoost Price TargetOverweight$23.00 ➝ $25.00N/A
i
4/28/2016WedbushBoost Price TargetNeutral$19.00 ➝ $23.00N/A
i
4/28/2016Stifel NicolausBoost Price TargetBuy$22.00 ➝ $25.00N/A
i
Rating by Rick Wise at Stifel Nicolaus
4/28/2016Royal Bank of CanadaBoost Price TargetOutperform$22.00 ➝ $25.00N/A
i
4/27/2016Needham & Company LLCBoost Price TargetBuy$22.00 ➝ $26.00N/A
i
Rating by Michael Matson at Needham & Company LLC
4/27/2016Evercore ISIBoost Price TargetBuy$21.50 ➝ $23.50N/A
i
4/27/2016BenchmarkReiterated RatingBuy$20.00 ➝ $22.00N/A
i
4/26/2016UBS GroupReiterated RatingBuyN/A
i
4/12/2016Royal Bank of CanadaBoost Price TargetOutperform$20.00 ➝ $22.00N/A
i
4/10/2016ArgusReiterated RatingHoldN/A
i
4/8/2016The Goldman Sachs GroupBoost Price Target$21.00 ➝ $22.00N/A
i
4/6/2016Stifel NicolausReiterated RatingBuy$22.00N/A
i
Rating by Rick Wise at Stifel Nicolaus
3/27/2016Morgan StanleyReiterated RatingOverweight$22.00N/A
i
3/25/2016Bank of AmericaReiterated RatingBuy$23.00N/A
i
3/18/2016Longbow ResearchInitiated CoverageBuyN/A
i
3/17/2016Nomura SecuritiesInitiated CoverageBuy$22.00N/A
i
3/12/2016Deutsche Bank AktiengesellschaftReiterated RatingHoldN/A
i
Rating by Kristen Stewart at Deutsche Bank Aktiengesellschaft
2/25/2016SunTrust BanksInitiated CoverageBuy$21.00N/A
i
2/9/2016Stifel NicolausReiterated RatingBuyN/A
i
Rating by Rick Wise at Stifel Nicolaus
2/7/2016Needham & Company LLCReiterated RatingBuy$22.00N/A
i
Rating by Michael Matson at Needham & Company LLC
2/7/2016BTIG ResearchReiterated RatingBuy$20.00N/A
i
Rating by Sean Lavin at BTIG Research
2/5/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
1/4/2016Sterne Agee CRTBoost Price TargetBuy$21.00 ➝ $22.50N/A
i
(Data available from 11/25/2015 forward)
Boston Scientific logo
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Read More

Today's Range

Now: $33.79
$33.61
$34.08

50 Day Range

MA: $37.05
$33.33
$41.97

52 Week Range

Now: $33.79
$24.10
$46.62

Volume

17,174,735 shs

Average Volume

10,759,086 shs

Market Capitalization

$48.38 billion

P/E Ratio

12.95

Dividend Yield

N/A

Beta

0.98